A ruthenium(II)-curcumin compound modulates NRF2 expression balancing the cancer cell death/survival outcome according to p53 status

ABSTRACT: BACKGROUND: Tumor progression and tumor response to anticancer therapies may be affected by activation of oncogenic pathways such as the antioxidant one induced by NRF2 (nuclear factor erythroid 2-related factor 2) transcription factor and the pathways modified by deregulation of oncosuppr...

Descripción completa

Detalles Bibliográficos
Autores principales: Garufi, Alessia, Baldari, Silvia, Pettinari, Riccardo, Gilardini Montani, Maria Saveria, D’Orazi, Valerio, Pistritto, Giuseppa, Crispini, Alessandra, Giorno, Eugenia, Toietta, Gabriele, Marchetti, Fabio, Cirone, Mara, D’Orazi, Gabriella
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325274/
https://www.ncbi.nlm.nih.gov/pubmed/32605658
http://dx.doi.org/10.1186/s13046-020-01628-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7325274/
https://www.ncbi.nlm.nih.gov/pubmed/32605658
http://dx.doi.org/10.1186/s13046-020-01628-5

Ejemplares similares